

Neuroprogressive & Dementia Network

NHS Tayside Parkinson's Research Update

January 2022



NEUROPROGRESSIVE
AND DEMENTIA

What we offer..

The Neuroprogressive & Dementia Network (NDN) is currently offering a wide variety of research opportunities to NHS Tayside patients. Areas of research includes (but is not limited to): Alzheimer's disease (AD), and Motor Neuron Disease (MND). Further-more, the types of research available varies from observational studies, e.g. completion of questionnaires, to clinical trials, e.g. the investigation of new potential treatments and medicinal products.

What's new?

Quite a lot has changed since our last update! We welcomed participants into our first MND trial, led by Dr Ian Morrison (Consultant Neurologist) and substantially increased our PD research activity, led by Dr Esther Sammler (Consultant Neurologist). We have also continued to expand the number of AD trials available within NHS Tayside (NHST) and been acknowledged as the fastest and highest recruiting site across multiple AD trials. More recently, we were delighted to be joined by two new team members: Dr Susan Angus (Consultant Psychiatrist) and Lorna Gillies (Parkinson's Nurse Specialist), who in addition to their clinical roles, are now working with us to support the recruitment and delivery of our ever-expanding research portfolio.

Get involved!

Our aim is to make research as accessible as possible. To do this, we have recently launched the "Neuroprogressive & Dementia Network Permission to Contact" (NDN PTC) system. The NDN PTC is a quick and easy referral system, whereby patients can chose to opt-in to hearing more about the network and potential research opportunities/study participation .

Neuroprogressive & Dementia Network

NHS Tayside Parkinson's Research Update

January 2022



NEUROPROGRESSIVE
AND DEMENTIA

Parkinson's Disease Research

TOPHAT—Dr Susan Angus/Leigh-Ann Whyte

Trial of Ondansetron as a Parkinson's Hallucinations Treatment

Open to new recruits? Yes

Study Drug? Yes: Ondansetron/Placebo

Inclusion criteria? >18yo, PD diagnosis, experiencing visual hallucinations

Participating Scottish sites? Dundee & Glasgow

RAPSODI GD—Dr Esther Sammler/Leigh-Ann Whyte

Remote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher disease

Open to new recruits? Yes

Study Drug? No: Observational

Inclusion criteria? Anyone with a diagnosis of Parkinson's Disease

Participating Scottish sites? Dundee

ABBVIE M15-737—Dr Esther Sammler/Tiffany Stewart

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion (96 week extension study)

Open to new recruits? No

Study Drug? Yes: 24hour sub-cutaneous levodopa/carbidopa infusion pump

Inclusion criteria? >30yo, idiopathic PD that is levodopa-responsive, already participated in M15-741)

Participating Scottish sites? Dundee 

ROPAD-II—Dr Esther Sammler/Tiffany Stewart/Lorna Gillies

Rostock International Parkinson's Disease Study Program: An International, Multicentre, Epidemiological Observational study

Open to new recruits? Yes

Study Drug? No: Observational

Inclusion criteria? 18-70yo, PD diagnosis or family member of participant with LRRK2 parkinsonism/member of high risk population

Participating Scottish sites? Dundee

LIPAD—Dr Esther Sammler/Lorna Gillies

Follow on to ROPAD, collecting further biological samples, currently recruiting

Neuroprogressive & Dementia Network

NHS Tayside Parkinson's Research Update

January 2022



NEUROPROGRESSIVE
AND DEMENTIA

Parkinson's Disease Research cont'd



CHIEF-PD—Dr Esther Sammler/Justine Hudson

Cholinesterase Inhibitor to prevent falls in Parkinson's Disease: A phase 3 randomised, double-blind placebo-controlled trial of Rivastigmine to prevent falls in Parkinson's disease

Open to new recruits? Yes

Study Drug? Yes: Rivastigmine/Placebo

Inclusion criteria? >18yo, PD diagnosis, experienced falls, able to walk without assistance

Participating Scottish sites? Dundee

PADOVA—Dr Esther Sammler/ Dr Adele Maxwell-Lindsay



A Phase IIB, randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early Parkinson's Disease

Open to new recruits? Yes

Study Drug? Prasinezumab/placebo

Inclusion criteria? >50-85yo, PD diagnosis 6M-3yr at screening, 3m stable treatment

Participating Scottish sites? Dundee

Upcoming research.....

EPSILON—Dr Esther Sammler/Leigh-Ann Whyte

Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson's Disease Patients

Open to new recruits? Soon!

Study Drug? Opicapone/placebo

Inclusion criteria? >30-80yo, Idiopathic PD diagnosis within 5 yr at screening, L-DOPA/DDCI treatment for at least 1 year.

Participating Scottish sites? Dundee

LRRK2 inhibitor trials still under review but looking promising!

Neuroprogressive & Dementia Network
NHS Tayside Parkinson's Research Update
January 2022



NEUROPROGRESSIVE
AND DEMENTIA

For more information about any of these trials and how you or someone you know can get involved, please contact the network office on 01382 423 086 or email tay.ndntayside@nhs.scot

Our research also support trials in other neuroprogressive disease's, including Alzheimer's Disease, Motor Neurone Disease and Huntington's. If you would like to hear more about any of our work or the work of our wider network in other health boards across Scotland, then please do not hesitate to get in touch using the contact details above.

Wishing you a happy and prosperous new year.